ADPEN Laboratories

The Analytical Partner You Trust

  • ABOUT ADPEN
    • CORONAVIRUS UPDATE:
    • Our Staff
    • Our Facilities
    • Our Instrumentation
  • CONTACT ADPEN
    • Request Info or Quote
  • TEST REQUEST FORMS
  • RESOURCES
    • Analytical Services and Testing Brochures
    • Career Opportunities
    • Industry Guidance Documents
    • Terms and Conditions
  • AGROSCIENCES
    • ANALYTICAL TESTING
    • ECOTOX
    • 5-BATCH ANALYSIS
    • PRODUCT CHEMISTRY
  • PHARMACEUTICALS
    • CONTRACT FORMULATION AND MANUFACTURING
    • PHARMACEUTICAL TESTING
    • NITROSAMINE IMPURITIES IN PHARMACEUTICALS
  • FOOD SAFETY
    • NUTRITIONALS
    • FOOD SAFETY TESTING
  • ANIMAL HEALTH
You are here: Home / ALL NEWS / All Services / FDA’s New Process Validation Guidance: Industry Reaction, Questions, and Challenges

FDA’s New Process Validation Guidance: Industry Reaction, Questions, and Challenges

October 3, 2011 By Steven Perez

FDA’s 2011 Process Validation: General Principles and Practices guidance created a systemic shift in industry’s approaches to validation programs. The authors describe the three-stage approach to validation that is outlined in the new guidance and discuss questions surrounding implementation.

In January 2011, FDA published its long-awaited guidance for industry on Process Validation: General Principles and Practices (1). For many in the pharmaceutical industry, the guidance created a systemic shift in the expectations of their validation programs. Although the new guidance aligns process-validation activities with the product life-cycle concept and with existing harmonized guidelines such as the International Conference on Harmonization’s Q8(R2) Pharmaceutical Development, Q9 Quality Risk Management, and Q10 Pharmaceutical Quality System, it may have created as many questions for the industry as it has answered. In this article, the authors briefly describe the three-stage approach to validation that is outlined in the new guidance as well as implications for manufacturers regarding their current approaches to process validation. Specific emphasis is placed on questions surrounding industry implementation.

Read more about industry’s reaction, questions and challenges to the FDA’s new process validation guidance at PharmTech.com.

Filed Under: All Services, Analytical Testing News & Updates | ADPEN Laboratories, Nutraceutical Links, Pharmaceutical Links Tagged With: analysis, Analytical, FDA, GMP, guidance, industry, Testing

ISO/IEC 17025 ACCREDITED

ISO/IEC 17025 is a company level accreditation based on a standard published by the International Organization for Standardization (ISO) titled “General requirements for the competence of testing and calibration laboratories”. ISO/IEC 17025 is a general umbrella term used to refer to the specific standard; the current version of this standard is ISO/IEC 17025:2017. The standard contains two main sections: management requirements (primarily related to the operation and effectiveness of the quality management system within the laboratory) and technical requirements (primarily related to the competence of staff and calibration of equipment). The standard also gives requirements related to quality management such as document control and corrective action. This standard is the basis for accreditation from an accrediting body.

ADPEN has also been inspected by the US-EPA and US-FDA multiple times with no observations.

Agroscience Links

  • 5-Batch Analytical Services
  • Analytical Testing Brochure
  • Pesticide Residue Analytical Services

Let’s Network!

Follow @AdpenLabs

RSS USEPA- Agriculture News

What Our Clients Say About ADPEN

“Good job by you and ADPEN!” -B.I.

Get in Touch With Us

ADPEN Laboratories, Inc.
11757 Central Parkway
Jacksonville, FL 32224 USA

Phone: 1.904.645.9169
Fax: (904) 641-8423
Contact Form

Copyright © 2021 · Enterprise Pro Theme on Genesis Framework · WordPress · Log in